LTRN
Lantern Pharma Inc. NASDAQ Listed Jun 11, 2020$3.79
-2.57%
vs $3.89
Mkt Cap $41.3M
52w Low $1.12
63.6% of range
52w High $5.32
50d MA $2.92
200d MA $3.23
P/E (TTM)
—
EV/EBITDA
—
P/B
0.0x
Debt/Equity
0.0x
ROE
-262.0%
P/FCF
-0.0x
RSI (14)
54.40
ATR (14)
$0.41
Beta
1.75
50d MA
$2.92
200d MA
$3.23
Avg Volume
294.4K
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
1920 McKinney Avenue · Dallas, TX 75201 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 15, 2026 | AMC | -0.36 | -0.30 | +16.7% | 3.14 | -6.1% | -4.5% | +3.0% | +2.6% | +4.7% | +5.4% | — |
| Mar 30, 2026 | AMC | -0.46 | -0.36 | +21.7% | 1.24 | +11.3% | +10.5% | +3.6% | +14.1% | +0.0% | +8.6% | — |
| Nov 12, 2025 | AMC | -0.46 | -0.39 | +15.2% | 3.48 | +2.9% | -0.6% | -2.3% | -0.6% | -4.5% | +1.9% | — |
| Aug 13, 2025 | AMC | -0.53 | -0.40 | +24.5% | 4.76 | -5.0% | -4.0% | +0.0% | -2.8% | +0.5% | +0.2% | — |
| May 15, 2025 | AMC | -0.49 | -0.42 | +14.3% | 3.86 | -1.6% | -14.0% | +8.1% | -3.1% | -4.0% | +0.3% | — |
| Mar 27, 2025 | AMC | -0.51 | -0.54 | -5.9% | 3.72 | +0.3% | -4.6% | -0.3% | -6.5% | +3.3% | -5.0% | — |
| Nov 7, 2024 | AMC | -0.56 | -0.42 | +25.0% | 3.42 | -2.0% | +12.3% | -8.6% | +2.0% | -1.4% | -1.1% | — |
| Aug 8, 2024 | AMC | -0.55 | -0.46 | +16.4% | 4.23 | +0.5% | -7.6% | -1.3% | +2.8% | -0.8% | +8.9% | — |
| May 9, 2024 | AMC | -0.43 | -0.51 | -18.6% | 6.81 | -9.7% | -9.5% | -1.1% | +1.6% | +2.3% | -3.0% | — |
| Mar 18, 2024 | AMC | -0.40 | -0.39 | +2.5% | 9.96 | -7.6% | -24.8% | +17.5% | +2.6% | +17.9% | -6.9% | — |
| Nov 8, 2023 | AMC | -0.45 | -0.29 | +35.6% | 2.80 | +5.0% | +33.2% | -11.5% | +14.2% | +8.2% | -1.7% | — |
| Aug 9, 2023 | AMC | -0.43 | -0.44 | -2.3% | 4.67 | +24.8% | +7.1% | -2.0% | -2.0% | -2.7% | -1.3% | — |
| May 9, 2023 | AMC | -0.48 | -0.36 | +25.0% | 5.60 | +0.0% | -0.5% | -3.2% | -2.8% | +1.1% | -10.4% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 10 | EF Hutton | Maintains | Buy → Buy | — | $4.67 | $5.83 | +24.8% | +7.1% | -2.0% | -2.0% | -2.7% | -1.3% |
| Jun 26 | EF Hutton | Maintains | Buy → Buy | — | $5.12 | $5.47 | +6.8% | +2.9% | -1.9% | +1.2% | -1.5% | +9.5% |
| May 18 | HC Wainwright & Co. | Maintains | Neutral → Neutral | — | $4.90 | $4.87 | -0.6% | -4.1% | +6.4% | +3.0% | -1.0% | +1.0% |
| Mar 21 | EF Hutton | Maintains | Buy → Buy | — | $4.65 | $4.87 | +4.7% | -5.4% | -1.6% | +3.5% | +0.8% | +1.4% |
| Feb 15 | EF Hutton | Maintains | Buy → Buy | — | $5.17 | $5.18 | +0.2% | +4.8% | -2.6% | +3.2% | -2.6% | -0.2% |
| Nov 1 | EF Hutton | Maintains | Buy → Buy | — | $4.19 | $4.35 | +3.8% | +5.3% | -3.4% | +4.0% | -2.9% | +4.0% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.55 | $6.99 | +6.7% | +4.4% | -8.6% | -2.4% | +9.8% | +4.3% |
| Nov 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.10 | $10.66 | +5.5% | -1.0% | +4.2% | -1.0% | -0.1% | -1.4% |
| Oct 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.49 | $9.90 | +4.3% | +8.0% | +7.7% | -3.2% | -0.1% | +3.2% |
| Jul 28 | Colliers Securities | Maintains | Buy → Buy | — | $12.64 | $12.64 | -0.0% | -3.3% | +1.2% | -1.3% | +0.8% | +1.6% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 12, 2026 | KEYSER D JEFFREYDir | — | Buy | 48,544 | $2.06 | $100K | 94,303 | +0.32% | +4.73% |
| May 12, 2026 | Schalop Lee TroyDir | — | Buy | 48,544 | $2.06 | $100K | 48,544 | +0.32% | +4.73% |
8-K · 7.01
! Medium
Lantern Pharma Inc. -- 8-K 7.01: Regulation FD Disclosure
Lantern Pharma disclosed a presentation to investors via SEC filing, likely signaling updates on pipeline programs or financial strategy that shareholders should review for material information.
Jun 2
8-K · 1.01
!! High
Lantern Pharma Inc. -- 8-K 1.01: Material Agreement
Lantern Pharma entered into a material agreement with ThinkEquity LLC, likely involving financing or capital raising services that could provide liquidity for the biopharmaceutical company's operations.
May 14
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Litron's Regulation FD disclosure of forward-looking statements from a presentation suggests upcoming product demonstrations or strategic initiatives, but investors should note these are unproven projections requiring careful scrutiny before trading decisions.
Apr 10
8-K · 7.01
! Medium
Unknown — 8-K 7.01: Regulation FD Disclosure
Lantern Pharma is hosting an earnings call to discuss 2025 full-year results, giving investors a chance to hear management commentary on operational performance and future guidance directly.
Mar 30
Institutional (13F) — Top 17
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Bios Capital Management, Lp | 1,009,507 | $3M | Reduced | Dec 2025 |
| 2 | Cm Management, Llc | 225,000 | $682K | — | Dec 2025 |
| 3 | Vanguard Capital Management Llc | 332,079 | $455K | New | Mar 2026 |
| 4 | Renaissance Technologies Llc | 116,000 | $159K | Added | Mar 2026 |
| 5 | Westside Investment Management, Inc. | 50,050 | $69K | Added | Mar 2026 |
| 6 | Voss Capital, Lp | 50,000 | $68K | — | Mar 2026 |
| 7 | Bank Of New York Mellon Corp | 21,301 | $29K | Reduced | Mar 2026 |
| 8 | Northern Trust Corp | 15,589 | $21K | — | Mar 2026 |
| 9 | Focus Partners Wealth | 15,432 | $21K | Reduced | Mar 2026 |
| 10 | Ubs Group Ag | 10,077 | $14K | Reduced | Mar 2026 |
| 11 | Morgan Stanley | 1,202 | $4K | — | Dec 2025 |
| 12 | Curio Wealth, Llc | 2,000 | $3K | — | Mar 2026 |
| 13 | Wells Fargo & Company/mn | 1,475 | $2K | New | Mar 2026 |
| 14 | Northwestern Mutual Wealth Management Co | 500 | $2K | — | Dec 2025 |
| 15 | Fmr Llc | 500 | $685 | New | Mar 2026 |
| 16 | Simplex Trading, Llc | 107 | $146 | Reduced | Mar 2026 |
| 17 | Jpmorgan Chase & Co | 97 | $120 | Added | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 12
All ↗
| # | Fund | Shares | Value | Period |
|---|---|---|---|---|
| 1 | Fidelity Extended Market Index Fund | 45,885 | $129K | Feb 2026 |
| 2 | Fidelity Total Market Index Fund | 15,273 | $43K | Feb 2026 |
| 3 | U.S. SMALL CAP PORTFOLIO | 12,797 | $40K | Jan 2026 |
| 4 | U.S. Social Core Equity 2 Portfolio | 10,400 | $33K | Jan 2026 |
| 5 | Fidelity Series Total Market Index Fund | 11,259 | $32K | Feb 2026 |
| 6 | iShares Micro-Cap ETF | 21,373 | $29K | Mar 2026 |
| 7 | Fidelity Nasdaq Composite Index Fund | 6,838 | $19K | Feb 2026 |
| 8 | U.S. CORE EQUITY 2 PORTFOLIO | 2,813 | $9K | Jan 2026 |
| 9 | Dimensional US Sustainability Core 1 ETF | 1,924 | $6K | Jan 2026 |
| 10 | Dimensional U.S. Core Equity 2 ETF | 1,042 | $3K | Jan 2026 |
| 11 | Dimensional US Core Equity 1 ETF | 4 | $13 | Jan 2026 |
| 12 | Dimensional US Vector Equity ETF | 4 | $13 | Jan 2026 |
Valuation
Market Cap
$41.3M
Enterprise Value
-$10.08B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
0.02x
P/B
0.01x
P/S
—
P/FCF
-0.00x
EV/EBITDA
—
Shares Out
10.9M
Financials (TTM)
Revenue
$0
Net Income
-$15.9M
EBITDA
-$15.9M
Free Cash Flow
-$15.68B
Op Cash Flow
-$15.68B
EPS Basic
$-1.57
EPS Diluted
$-1.45
EPS Forward
$-1.74
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$11.04B
Total Liab.
$4.50B
Total Equity
$6.53B
Cash
$10.12B
LT Debt
$0
Book Value/Sh
$599.58
Debt/Equity
0.01x
Current Ratio
2.40
Quick Ratio
2.40
Returns & Growth
ROE
-262.0%
ROA
-155.1%
ROIC
-0.3%
Rev Growth YoY
+0.0%
EPS Growth YoY
+99.9%
Price Returns
2W
+14.7%
1M
+75.1%
3M
+27.3%
6M
-0.8%
12M
+17.7%
Technicals
52W High
$5.32
52W Low
$1.12
50d MA
$2.92
200d MA
$3.23
RSI (14)
54.40
ATR (14)
$0.41
Beta
1.75
Avg Volume
294K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
—
High
—
Low
—
Median
—
Data updated apr 25, 2026 8:01pm
· Source: financialmodelingprep.com